TAL61 / Talus Bio - LARVOL DELTA

Poster 4036 / 2: Selective inhibition of the transcription factor Brachyury in chordoma and non-small cell lung cancer (Businesswire) - "Preclinical data presented by Gaelle Mercenne at AACR showcase the ability of a novel covalent small molecule, TAL61, to effectively modulate Brachyury activity in patient-derived xenograft (PDX) models of chordoma: TAL61 demonstrated significant efficacy in reducing tumor burden in PDX chordoma models with durable tumor suppression post-treatment; TAL61 exhibited low toxicity and high tolerability with daily dosing; Additionally, TAL61 decreased tumor burden by more than 50% in in vivo models of Brachyury-positive non-small cell lung cancer (NSCLC)."

Preclinical • Chordoma • Non Small Cell Lung Cancer